More importantly, in a xenograft ovarian cancer mouse model, the therapeutic delivery of siRNA targeting FABP4 in tumor vessels inhibited the tumor angiogenesis and peritoneal metastasis of ovarian cancer [48]. This evidence concerns the gene FABP4 and neoplasm.